Evolución de la diabetes mellitus tipo 2 en pacientes obesos mórbidos después del by pass gástrico
Palabras clave:
medicina, tesis doctorales, diabetes mellitus tipo 2, obesidad en diabéticos, obesidad, cirugía, bypass gástricoResumen
En este trabajo se pretende demostrar si el bypass gástrico en Y de Roux produce mejoría o remisión de Diabetes Mellitus tipo 2 en pacientes obesos mórbidos. Establecer si el descenso d peso está relacionado con mejoría de glucemia, insulinemia y hemoglobina glicosilada. En los casos analizados a los 18 meses post bypass gástrico en Y de Roux, la remisión total de la diabetes fue del 76,6%. Sólo el 23,3% de peor control metabólico requirieron medicación en el postoperatorio. El descenso de la HbA1c fue el indicador de mejoría de Diabetes Mellitus tipo 2. Podemos decir que el BPGY es una técnica apropiada para el tratamiento de dicha enfermedad.Descargas
Referencias
WHO. 2000, Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser, 894:i-xii, 1-253.
Haslam DW, James WP. 2006, Obesity. Lancet, 366(9492):1197-209. https://doi.org/10.1016/S0140-6736(05)67483-1
Willett WC, Dietz WH, Colditz GA. 1999, Guidelines for healthy weight. N Engl J Med, 341(6):427-34. https://doi.org/10.1056/NEJM199908053410607
Schelbert, KB. 2009, Comorbidities of obesity. Prim Care, 36(2):271-85. https://doi.org/10.1016/j.pop.2009.01.009
Nguyen NT, Magno CP, Lane KT, et al. 2008, Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg, 207(6):928-34. https://doi.org/10.1016/j.jamcollsurg.2008.08.022
Sjostrom CD, Lissner L, Wedel H, Sjoström L. 1999, Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res, 7(5):477-84. https://doi.org/10.1002/j.1550-8528.1999.tb00436.x
Wilson PW, D'Agostino RB, Sullivan L, et al. 2002, Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med, 162(16):1867-72. https://doi.org/10.1001/archinte.162.16.1867
Saydah SH, Fradkin J, Cowie CC. 2004, Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA, 291:335-42. https://doi.org/10.1001/jama.291.3.335
Buchwald H, Estok R, Fahrbach K, et al. 2009, Weight and type 2 diabetes after bariatric surgery: systematic review and metaanalysis. Am J Med, 122(3):248.e5-256.e5. https://doi.org/10.1016/j.amjmed.2008.09.041
Pories WJ, Swanson MS, MacDonald KG, et al. 1995, Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg, 222:339-50. https://doi.org/10.1097/00000658-199509000-00011
Rubino, F. 2008, Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes care, 31(Suppl 2): s290-6. https://doi.org/10.2337/dc08-s271
Creutzfeldt, W. 1979, The incretin concept today. Diabetologia, 16(2):75-85. https://doi.org/10.1007/BF01225454
Creutzfeldt, W. 2005, The [pre-] history of the incretin concept. Regul Pept, 128(2):87-91. https://doi.org/10.1016/j.regpep.2004.08.004
Holst, JJ. 2007, The physiology of glucagon-like peptide 1. Physiol Rev, 87(4):1409-39. https://doi.org/10.1152/physrev.00034.2006
ADA. 2012, Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 35(Supplement 1):S64-S71. https://doi.org/10.2337/dc12-s064
Nathan DBT, Buse JB, Davidson MB, et al. 2009, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32:193-203. https://doi.org/10.2337/dc09-0271
Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, et al. 2012, Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. N Engl J Med, 366(17):1567-76. https://doi.org/10.1056/NEJMoa1200225
Klein S, Burke LE, Bray GA, et al. 2004, Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Found. Circulation, 110(18):2952-67. https://doi.org/10.1161/01.CIR.0000145546.97738.1E
Cummings, DE. 2009Endocrine metabolisms mediating remision of diabetes after gastric bypass surgery., Int J Obes (Lond), 33(suppl 1):S33-40. https://doi.org/10.1038/ijo.2009.15
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7):539-53. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
ECDCDM, The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 26(suppl 1):s5-s20 . https://doi.org/10.2337/diacare.26.2007.S5
Danaei G, Finucane M, Lu Y, Singh G, Cowan M, Paciorek C, et al. 2011,National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2,7 million participants. Lancet, 378:31-40. https://doi.org/10.1016/S0140-6736(11)60679-X
IDF, International Diabetes Federation. New estimales for 2012 of diabetes prevalence, mortality, and healthcare expenditures. Update. 5th ed. International Diabetes Federation. [En línea] 2012. http:// www.idf.org/diabetesatlas/5e/LJpdate2012.
Hermán WH, Zimmet P. 2012, Type 2 Diabetes: An epidemia requiring global attention and urgent action. Diabetes Care, 35:943-44. https://doi.org/10.2337/dc12-0298
ONU. Resolución Asamblea General Naciones Unidas. A/ RES/61/225. ONU. [En línea] 18 de Enero de 2007. www.gawh.org/issues/diabetes/UN_diabetes_resolution_spanish.pdf.
ADA, American Diabetes Association. 2013, Diagnosis and classification of diabetes mellitus. Diabetes Care, 36:67S-74S. https://doi.org/10.2337/dc13-S067
Taylor K, Heneghan C, Farmer A, Fuller A, Adler A, Aronson J, et al. 2013, All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. Primary Care Database. Diabetes Care, 36(8):2366- 71. https://doi.org/10.2337/dc12-1513
Mac Farlane IA, Bliss M, Jackson JGL, Williams G. Diabetes in its historical and social context: The history of diabetes mellitus. En: Williams G, editors Pickup IC. Textbook of diabetes. 2da. ed. Oxford : Black Well Science Ltd, 1997, 1.1.1-1.1.21.
Anjos S, Polychronakos C. 2004, Mechanisms of genetic susceptibility to type I diabetes: beyond HLA. Mol Genet Metab, 81:187-95.
https://doi.org/10.1016/j.ymgme.2003.11.010
Hober D, Alidjinou EK. 2013,Enteroviral pathogenesis of type 1 diabetes: queries and answers. Curr Opin Infect Dis, 26(3):263-9. https://doi.org/10.1097/QCO.0b013e3283608300
King KM, Rubin G. 2003, A history of diabetes: from antiquity to discovering insulin. Br J Nurs, 12(18):1091-5. https://doi.org/10.12968/bjon.2003.12.18.11775
Goodman-Gilman A, Rall TW, Nies AS, Taylor P. Goodman y Gilman, las bases farmacológicas de la terapéutica. 8ª ed. en español. Barcelona: McGraw-HillInteramericana, 1991.
Godfine ID, Youngren JF. 1998, Contributions of the American Journal of Physiology to the discovery of insulin. Am J Physiol, 274:E207-E208. https://doi.org/10.1152/ajpendo.1998.274.2.E207
Martí, ML. 1972, Las primeras aplicaciones de insulina en Buenos Aires. Rev Arg Med Int, 3:245.
Serantes, NA. Vivencias, medio siglo con la diabetología argentina. Buenos Aires Librería Akadia Editorial, 1992.
Poole, G. 1953, Intercapillary glomerulosclerosis and the Kimmelstiel-Wilson Syndrome. Postgrad Med J, 29:137-146. https://doi.org/10.1136/pgmj.29.329.137
Loubatières-Mariani, MM. 2007, The discovery of hypoglycemic sulfonamides. J Soc Biol, 201(2):121-5. https://doi.org/10.1051/jbio:2007014
Cardonnet, LJ. 1970, Pasado, presente y futuro de la Sociedad Argentina de Diabetes. Rev Soc Arg de Diabetes, 4:47.
Lapertosa S, González C, Benitez J, et al. 2009 Prevalencia de la diabetes mellitus tipo 2 en población adulta de Gobernador Virasoro. Provincia de Corrientes., Rev ALAD, XVII(3).
Goday Arno G, Flores Le Roux J. Capítulo 2: Epidemiología de la Diabetes Mellitus. En: Escobar Jiménez F Tébar Massó FJ. La Diabetes en la Práctica Clínica. Buenos Aires, Argentina: Editorial Panamericana, 2009, 11-18.
Schargrodsky H, Hernández-Hernández R, Champagne BM, Silva H, Vinueza R, Silva Ayçaguer LC, et al. 2008, CARMELA Study Investigators. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med, 121:58-65. https://doi.org/10.1016/j.amjmed.2007.08.038
Filozof C, González C, Sereday M, et al. 2001, Obesity prevalence and trends in Latin America Countries. Obesity Reviews, 2:99-106. https://doi.org/10.1046/j.1467-789x.2001.00029.x
Sereday MS, Gonzalez C, Giorgini D, De Loredo L, Braguinsky J, Cobeñas C, Libman C, Tesone C. 2004, Prevalence of diabetes, obesity, hypertension and hyperlipidemia in the central area of Argentina. Diabetes Metab, 30(4):335-9. https://doi.org/10.1016/S1262-3636(07)70125-8
ENFR. Encuesta Nacional de Factores de Riesgo. Ministerio de Salud. [En línea] 2005. www.msal.gob.ar.
Valdés S, Rojo-Martínez G, Soriguer F. 2007, Evolución de la prevalencia de la diabetes tipo 2 en población adulta española. Med Clin (Barc), 129(9):352-5. https://doi.org/10.1157/13109554
ADA, American Diabetes Association. 2013, Standard of Medical Care in Diabetes-2013. Diabetes Care, 36(Suppl1):S27-S28. https://doi.org/10.2337/dc13-S011
Shaw JE, Zimmet PZ, Hodge AM, de Courten M, et al. 2000, Impared fasting glucose: how low should it go? Diabetes Care, 23:34-30. https://doi.org/10.2337/diacare.23.1.34
ADA, American Diabetes Association. 2010, Position Statement. Diagnosis and Classification of Diabetes Mellitus.Diabetes Care, 33:S62-S69. https://doi.org/10.2337/dc10-S062
Meigs JB, Cuppples LA, Wilson PW. 2000, Parenteral Transmition of type 2 diabetes: The Framinghan Off Spring Study. Diabetes, 49(12):2201-7. https://doi.org/10.2337/diabetes.49.12.2201
Shaijian R, Manson JE, Stamptes MJ, et al. 2006, Ethnicity, obesity, and risk of type 2 diabetes in women: a 20 fears follow-up study 17. Diabetes Care, 29(7):1585-90. https://doi.org/10.2337/dc06-0057
SAD, Sociedad Argentina de Diabetes. 2007, Consenso sobre criterio diagnóstico de la glucemia alterada de ayunas. Rev Soc Arg Diabetes, 41(3):95-106.
Musso C, Litwak L, Sinay I. 2014, Importancia del manejo de la glucosa postprandial en la diabetes tipo 2. Tratamiento y nuevas terapéuticas. Rev Soc Argent Diabetes, 48(1):11- 21. https://doi.org/10.47196/diab.v48i1.179
Gore MO, Maguire DK. 2009, The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diabetes Vasc Dis Res, 6:53-55. https://doi.org/10.3132/dvdr.2009.012
Forouhi NG, Balkau B, Borch-Johnsen K, et al. 2006, On behalf of EDEG.The threshold for diagnosing impaired fasting glucose: a position Statement by the European Diabetes Epidemiology Group. Diabetologia, 49:822-827. https://doi.org/10.1007/s00125-006-0189-4
Gómez Pérez FJ, Aguilar Salinas CA, et al. 1988, Lack of agreement between the World Health Organization category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose. Diabetes Care, 21:1886-1888. https://doi.org/10.2337/diacare.21.11.1886
EDEG, The DECODE Study group on behalf of the European Diabetes Epidemiology Group. 1999, Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 354:617-621. https://doi.org/10.1016/S0140-6736(98)12131-1
EDEG, The DECODE Study Group. 2003, Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and no cardiovascular diseases? Diabetes Care, 26:688-696. https://doi.org/10.2337/diacare.26.3.688
CDA, Canadian Diabetes Association. Canadian Diabetes Association 2008 Clinical Practice Guidelines. 2008, Definition, classification and diagnosis of diabetes and other dysglycemic categories. Can J Diabetes, 32(suppl 1):S10-S13.
ADA. 2007, Summary of Revisions for the 2007. Clinical Practice Recommendations. Diabetes Care, 30 (Suppl 1): S3. https://doi.org/10.2337/dc07-S003
Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. 2005, The metabolic syndrome-a new worldwide definition. The Lancet, 366(9491):1059-1062. https://doi.org/10.1016/S0140-6736(05)67402-8
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. 2005, Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112:2735-2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404
de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. 1998, The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabetes Care, 21(10):1686-90. https://doi.org/10.2337/diacare.21.10.1686
Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, et al (Look AHEAD Research Group). 2007, Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care, 30(6):1374-83. https://doi.org/10.2337/dc07-0048
King H, et al. 1998, Global Burden of Diabetes 1995-2025. Diabetes Care, 9(21):1414- 1431. https://doi.org/10.2337/diacare.21.9.1414
Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. 2009, Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore.BMJ, 338:880. https://doi.org/10.1136/bmj.b880
Harris, MI. 1997, Prevalence of Diabetes, impaired fasting glucose and impaired glucose tolerance in US Adults (The Nhanes III). Diabetes Care, 4(21):518-524. https://doi.org/10.2337/diacare.21.4.518
IDF, International Diabetes Federation. IDF Consensus worldwide definition of the metabolic syndrome. IDF. En: 2006. http://www.idf.org/webdata/docs/ IDF_Meta_def_final.pdf.
Lindström J, Tuomilehto J. 2003, The Diabetes Risk Score. A practical tool to predict type 2 diabetes risk. Diabetes Care, 26:725-731. https://doi.org/10.2337/diacare.26.3.725
Durruty P, García de los Ríos M. Bases Bioquímicas y fisiopatológicas de la diabetes mellitus. En: Durruty P García de los Ríos M. Diabetes mellitus. Santiago, Chile: Arancibia Hnos, 2003, 56-66.
Dichgans M, Hegele RA. 2009, Update on the genetics of stroke and cerebrovascular disease 2008. Stroke, 40(5):e289-91. https://doi.org/10.1161/STROKEAHA.108.544569
Doria A, OnumaT, Warram JH, et al. 1997, Synergistic effect of angiotensin II type I receptor genotype and poor glycemic control on risk of nephropathy in IDDM. Diabetologia, 40:1239-9. https://doi.org/10.1007/s001250050823
Fogarty DG, Harron JC, Hughes AE, Nevin NC, Doherty CC, Maxwell AP. 1996, A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes, 45(9):1204-8. https://doi.org/10.2337/diab.45.9.1204
Conway BR, Maxwell AP. 2009, Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases? Nephron Clin Pract, 112(4):c213-21. https://doi.org/10.1159/000224787
Doria A, Warram JH, Krolewski AS. 1994, Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes, 43:690-5. https://doi.org/10.2337/diabetes.43.5.690
Dudley CRK, Keavney B, Statton IM, et al. 1995, UK Prospectivo Diabetes Study XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM. Kidney Int, 48:1907-11. https://doi.org/10.1038/ki.1995.490
Lorenzo C, Serrano-Ríos M. Epidemiology of the metabolic syndrome. En: Caro JF, Carraro R, Gutiérrez-Fuentes JA (eds) Serrano-Ríos M. The Metabolic Syndrome at the beginning of the XXIst century. Madrid, España: Fundación Lilly, 2005, 109-129. https://doi.org/10.1016/B978-84-8174-892-5.50007-3
Philip W, James T. 2005, The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. EHJ Supplements, 7(Suppl L):L44-L48. https://doi.org/10.1093/eurheartj/sui086
King P, Peacock I, Donnelly R. 1999, The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol, 48(5):643- 648. https://doi.org/10.1046/j.1365-2125.1999.00092.x
Knowler WC, Pettitt DJ, Savage PJ, Bennett PH. 1981, Diabetes incidence in PIMA indians: contribution of obesity and parental diabetes 1. Am J Epidemiol, 113(2):144-156. https://doi.org/10.1093/oxfordjournals.aje.a113079
Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, Walker M, Ferrannini E y Group, EGIR-RISC Study. 2004, The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia, 47(3):566-70 https://doi.org/10.1007/s00125-004-1335-5
Reaven, GM. 1988, Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37:1595-607. https://doi.org/10.2337/diabetes.37.12.1595
Howard G, Burke GL, Szklo M, Tell GS, Eckfeldt J, Evans G, Heiss G. 1994, Active and passive smoking are associated with increased carotid wall thickness: the atherosclerosis risk in communities study. Arch Intern Med, 154:1277-1282. https://doi.org/10.1001/archinte.1994.00420110125014
Araujo TG, Oliveira AG, Saad MJ. 2013, Insulin-resistance-associated compensatory mechanisms of pancreatic Beta cells: a current opinion. Front Endocrinol (Lausanne), 4:146. https://doi.org/10.3389/fendo.2013.00146
Dufayet De La Tour D, Raccah D, Jannot MF, et al. 1998, Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia, 41:1080-4. https://doi.org/10.1007/s001250051033
Earle K, Walker J, Hill C, et al. 1992, Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. NEJM, 326:673-7. https://doi.org/10.1056/NEJM199203053261005
De Fronzo, RA. 2009, From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes Care, 58:773-95. https://doi.org/10.2337/db09-9028
Hammond A, Mady G. 2001, Correction formula for carbamylated hemoglobin in diabetic uremic patients. Ann Clin Biochem, 38:115-9. https://doi.org/10.1258/0004563011900407
WHO, Expert committe on diabetes mellitus. Expert committe on diabetes mellitus: second report. World Health Org. Tech. Rep. Ser. N° 646, 1985 and 1994. Geneve: WHO, 1995.
Blotner, H. 1947, Sugar tolerance test: Methods and evaluation. Amer J Diag Dis, 14:245. https://doi.org/10.1007/BF03001279
ADA, American Diabetes Association. 1969, Standarization of oral tolerance tests. Report of the Committe on statistics. June 14. 1968. Diabetes, 18:299. https://doi.org/10.2337/diab.18.5.299
Cohn, JW. 1940, Interpretation of the glucose tolerance test. The necessity of standard preparatory diet. Am J Med Sci, 199:55. https://doi.org/10.1097/00000441-194004000-00014
Dipaola G, Robín M, Delfino M. 1970, Estrogenoterapia y metabolismo hidrocarbonado. Rev Arg de Ginec Obstet, 1:3.
Jarret R, Keen H. 1969, Diurnal variations and glucose tolerance. Diabetologia, 5:201.
Haggard HN, Greenberg L. 1934, The effects of cigarette smoking on blood sugar. Science, 79:165. https://doi.org/10.1126/science.79.2042.165
Reinheimer W, Davidson P, Albrinik M. 1968, Effect of moderate exercise on plasma glucose, insulin and free fatty acids during oral glucose tolerance tests.J Lab Clin Med, 71:429.
Garry, J. 1993, Enzyme immunoassay. A new technique for estimating hemoglobin A1e. Clin Chem, 39:663-6. https://doi.org/10.1093/clinchem/39.4.663
Laurence M, Demers C. 1993, A rapid method of glycohemoglobin. Clin Chem, 39:363. https://doi.org/10.1093/clinchem/39.2.363
David H, Wilson D. 1993 Fully automated assay of glycohemoglobin., Clin Chem, 39:2090-7. https://doi.org/10.1093/clinchem/39.10.2090
Berntrop, K. 1983, Relation between plasma insulin and blood glucose in a cross-sectional population study of the oral glucose tolerance test. Act Endocr, 102:549-56. https://doi.org/10.1530/acta.0.1020549
Pfeifer, MA. 1981, Insulinsecretion in diabetes mellitus. Am J Med, 70:579-588. https://doi.org/10.1016/0002-9343(81)90579-9
Flegal KM, Carroll MD, Kit BK, Ogden CL. 2012, JAMA, Prevalence obesity and trends in the distribution of body mass index among US adults, 1999-2010. 307(5):491-97. https://doi.org/10.1001/jama.2012.39
Ghandehari H, Le V, Kamal-Bahl S, Bassin S, Wong N. 2009, Abdominal obesity and the spectrum of global cardiometabolic risks in US adults. Int J Obesity, 33:239-48. https://doi.org/10.1038/ijo.2008.252
Gami A, Witt B, Howard D, Erwin P, Gami L, Somers V et al. 2007, Metabolic Syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol, 49:403-14. https://doi.org/10.1016/j.jacc.2006.09.032
Cornier M, Dabelea D, Hernández T, Lindstrom R, Steig A, Stob N et al. 2008, The metabolic syndrome.Endocr Rev, 29:777-822. https://doi.org/10.1210/er.2008-0024
Basterra-Gotari FJ, Buenza JJ, Bes-Rastrollo M, Toledo E, García-López M, MartínezGonzález MA. 2011, Tendencia creciente de la prevalencia de la obesidad mórbida en España: de 1.8 a 6.1 por mil en 14 años. Rev Esp Cardiol, 64(5):424-6. https://doi.org/10.1016/j.recesp.2010.06.010
Pou K, Massaro J, Hoffmann U, Lieb K, Vasan R, O'Donnell C et al. 2009, Patterns of abdominal fat distribution. The Framingham heart study. Diabetes Care, 32:481-85 https://doi.org/10.2337/dc08-1359
Ezquerra EA, Castellano-Vázquez JM, Barrero AJ. 2008. Obesidad, síndrome metabólico y diabetes: implicaciones cardiovasculares y actuación terapéutica. Rev Esp Cardiol, 2008, 61:752-64. https://doi.org/10.1157/13123996
Zimmet P, Alberti KG, Shaw S. 2001. Global and societal implications of diabetes epidemic. Nature, 414: 782-74.
https://doi.org/10.1038/414782a
Muntoni, S. 2011, Insulin resistance: pathophysiology and rationale for treatment. Ann Nutr Metab, 58:25-36. https://doi.org/10.1159/000323395
Gallager E, Le Roith D, Karnieli E. 2008 The metabolic syndrome from insulin resistance to obesity and diabetes., Endocrinol Metab Clin North Am, 37:559-79. https://doi.org/10.1016/j.ecl.2008.05.002
Lara-Castro C, Garvey W. 2008 Intracellular Lipid Accumulation in Liver and Muscle and the Insulin Resistance Syndrome., Endocrinol Metab Clin North Am, 37:841-56. https://doi.org/10.1016/j.ecl.2008.09.002
Reaven, GM. 2005, The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr, 83:1237-47. https://doi.org/10.1093/ajcn/83.6.1237
Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, Collins D y (VA-HIT), Veterans Affairs HDL Intervention Trial. 2003, Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care, 26(5):1513-7. https://doi.org/10.2337/diacare.26.5.1513
Savage D, Semple R, Clatworthy M, Lyons P, Morgan B, Cochran E, et al. 2009, Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab, 94:10-16. https://doi.org/10.1210/jc.2008-1703
Ford E, Li C, Saltar N. 2008, Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care, 31:1898-904. https://doi.org/10.2337/dc08-0423
McQuillan GM, McLean JE, Chiappa M, Corporation H, Lukacs SL. 2015, National Health and Nutrition Examination Survey Biospecimen Program: NHANES III (1988- 1994) and NHANES 1999-2014. Vital Health Stat 2, 170:1-14.
Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, et al. 2002, National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation, 106(25):3143- 3421. https://doi.org/10.1161/circ.106.25.3143
Sun K, Kusminski C, Scherer P. 2011, Adipose tissue remodeling and obesity. J Clin Invest, 121:2094-101. https://doi.org/10.1172/JCI45887
Mattu H, Randeva H. 2013, Role of adipokines in cardiovascular disease. J Endocrinology, 216:17-36. https://doi.org/10.1530/JOE-12-0232
Rosenzweig J, Ferrannini E, Grundy S, HaffnerS, Heine R, Horton E et al. 2008, Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 93:3671-89. https://doi.org/10.1210/jc.2008-0222
Dahlman I, Arner P. 2007, Obesity and polymorphisms in genes regulating human adipose tissue. Int J Obes, 31:1629-41.
https://doi.org/10.1038/sj.ijo.0803657
De Fronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Barón AD. 2005 Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes., Diabetes Care, 28:1092-100. https://doi.org/10.2337/diacare.28.5.1092
Walker B, Andrew R. 2006, Tissue production of cortisol by ll betahydroxysteroid dehydrogenase type 1 and metabolic disease. Ann N Y Acad Sci, 1083:165-84. https://doi.org/10.1196/annals.1367.012
Knowler W, Barrett-Connor E, Fowler S, Hamman R, Lachin J, Walker E et al. 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346:393-403. https://doi.org/10.1056/NEJMoa012512
Ashrafian H, Athanasiou T, Li JV, Bueter M, Ahmed K, Nagpal K, et al. 2001, Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes Rev, 12:e257-72. https://doi.org/10.1111/j.1467-789X.2010.00802.x
Maida A, Lamont B, Cao X, Drucker D. 2011, Metformin regulates the incretin receptor axis vía a pathway dependent on peroxisome proliferator-activated receptor-a in mice. Diabetologia, 54:339-49. https://doi.org/10.1007/s00125-010-1937-z
UKPDS, UK Prospective Diabetes Study Group. 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet, 352(9131):854-65. https://doi.org/10.1016/S0140-6736(98)07037-8
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR, Trial Investigators Group. 2006 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication), Lancet, 368(9541):1096-105.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. 2004, XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care, 27(1):155-161. https://doi.org/10.2337/diacare.27.1.155
Adams T, Gress R, Smith S, Halverson R, Simper S, Rosamond W et al. 2007, Longterm mortality after gastric bypass surgery. N Engl J Med, 357:753-61. https://doi.org/10.1056/NEJMoa066603
García-Castellanos J, Andino S, Cooke J, Clariá J, Matus G. 20163; Estenosis de la Anastomosis Gastroyeyunal como Complicación de la Derivación Gástrica en Cirugía Bariátrica. Reporte de Casos y su Manejo. Buenos Aires : 84º Congreso Argentino de Cirugía, XX Congreso Latinoamericano de Cirugía FELAC. Folio Nº 102 (XXII).
ADA, American Diabetes Association. 2016, Standards of medical care in diabetes2016. Diabetes Care, 39(suppl 1):S1-S106.
Albala C, Reyes M. Evolución natural y riesgos de la obesidad. En: Csendes A, Guzmán S, Awad W Burdiles P. Obesidad y cirugía bariátrica. Santiago, Chile : Ed. Mediterráneo, 2012, 39-49.
Buchwald H, Avidor Y, Braunwald E, et al. 2004, Bariatric surgery: a systematic review and meta-analysis. JAMA, 292(14):1724-37. https://doi.org/10.1001/jama.292.14.1724
Vetter ML, Cardillo S, Rickels MR, Iqbal N. 2009, Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med, 150:94-103. https://doi.org/10.7326/0003-4819-150-2-200901200-00007
NIH. 1991, Gastrointestinal surgery for severeobesity. Consensus Development Conference Panel. Ann Intern Med, 115:956-61. https://doi.org/10.7326/0003-4819-115-12-956
Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. 2004, Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med, 351:2683-93. https://doi.org/10.1056/NEJMoa035622
Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. 2004, Adjustable gastric banding and conventional therapy for type 2 diabetes. A randomized controlled trial. JAMA, 299:316-23. https://doi.org/10.1001/jama.299.3.316
Dixon JB, Le Roux CW, Rubino F, Zimmet P. 2012, Bariatric surgery of type 2 diabetes. Lancet, 379(9833):2300-11. https://doi.org/10.1016/S0140-6736(12)60401-2
Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KGMM, et al, on behalf of the Delegates of the 2nd Diabetes Surgery Summit. 2016, Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care, 39:861-877. https://doi.org/10.2337/dci16-0031
Csendes A, Papapietro K, Burgos AM, Lanzarini E, Canobra M. 2011, Efecto del bypass gástrico a largo plazo (7 a 10 años) en pacientes con obesidad severa y mórbida sobre el peso corporal, diabetes, dislipidemia y desarrollo de anemia. Rev Med Chile, 139:1414-20. https://doi.org/10.4067/S0034-98872011001100004
Nora M, Guimaraes M, Almeida R, et al. 2011, Metabolic laparoscopic gastric bypass for obese patients with type 2 diabetes. Obes Surg, 21(11):1643-49. https://doi.org/10.1007/s11695-011-0418-x
Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW et. 2011, Obesity and type 2 diabetes: what can be unified and what needs to be Diabetes Care, 34:1424-30. https://doi.org/10.2337/dc11-0447
Wittgrove AC, Clark GW, Tremblay LJ. Laparoscopic Gastric Bypass, Roux-en-Y: Preliminary Report of Five Cases. Obes Surg 1994; 4(4):353-357. https://doi.org/10.1381/096089294765558331
Cottam D, Qureshi FG, Mattar SG, et al. 2006, Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity. Surg Endosc, 20(6):859-63. https://doi.org/10.1007/s00464-005-0134-5
Ramos AC, Galvao Neto MP, de Souza YM, et al. 2009, Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI<30 kg/m2 (LBMI). Obes Surg, 19(3):307-12. https://doi.org/10.1007/s11695-008-9759-5
Hess DS, Hess DW, Oakley RS. 2005, The biliopancreatic diversion with the duodenal switch: results beyond 10 years. Obes Surg, 15:408-416. https://doi.org/10.1381/0960892053576695
Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. 2012, Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care, 35:1420-28. https://doi.org/10.2337/dc11-2289
Steffen, R. 2008, The history and role of gastric banding. Surg Obes Relat Dis, 4(3 Suppl):S7-13. https://doi.org/10.1016/j.soard.2008.04.002
Lahsen R, Berry M. 2010, Surgical interventions to correct metabolic disorders. Br J Diabetes Vasc Dis, 10:143-47. https://doi.org/10.1177/1474651410370302
González-Santamaría JR, Girón-Márquez J, Limón-Aguilar JL, Márquez-Aldama G. 2005, Bypass gástrico. Tratamiento quirúrgico de la obesidad mórbida. Rev Hosp Jua Mex, 72(4):153-160.
Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, et al. 2009, Consensus Statement: how do we define cure of diabetes? Diabetes Care, 32:2133-35. https://doi.org/10.2337/dc09-9036
Dixon JB, Zimmet P, Alberti KG, Rubino F. 2011, International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery: and IDF statement for obese type 2 diabetes. Diabet Med, 28:628-42. https://doi.org/10.1111/j.1464-5491.2011.03306.x
Del-Rosso A, Cerinic MM, De-Giorgio F, Minari C, Rotella CM, Seghier G. 2006, Rheumatological manifestations in diabetes mellitus. Curr Diabetes Ver, 2:455-66. https://doi.org/10.2174/1573399810602040455
Ducloux R, Nobécourt E, Chevallier MJ, Ducloux H, Elian N, Altman JJ. 2011, Vitamin D deficiency before bariatric surgery: should supplement intake be routinely prescribed? Obes Surg, 21:556-500. https://doi.org/10.1007/s11695-010-0352-3
Papapietro K, Díaz E, Csendes A, Díaz JC, Braghetto I, Burdile P et al. 2005, Evolución de comorbilidades metabólicas asociadas a obesidad después de cirugía bariátrica. Rev Med de Chile, 133:511-16. https://doi.org/10.4067/S0034-98872005000500001
